TAZVERIK Drug Patent Profile
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
Which patents cover Tazverik, and when can generic versions of Tazverik launch?
Tazverik is a drug marketed by Epizyme Inc and is included in one NDA. There are twenty-three patents protecting this drug.
This drug has three hundred and twenty-four patent family members in thirty-eight countries.
The generic ingredient in TAZVERIK is tazemetostat hydrobromide. Additional details are available on the tazemetostat hydrobromide profile page.
DrugPatentWatch® Generic Entry Outlook for Tazverik
Tazverik will be eligible for patent challenges on January 23, 2024. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be December 19, 2035. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
Summary for TAZVERIK
| International Patents: | 324 |
| US Patents: | 23 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 64 |
| Clinical Trials: | 9 |
| Patent Applications: | 365 |
| Drug Prices: | Drug price information for TAZVERIK |
| What excipients (inactive ingredients) are in TAZVERIK? | TAZVERIK excipients list |
| DailyMed Link: | TAZVERIK at DailyMed |
DrugPatentWatch® Estimated Generic Entry Opportunity Date for TAZVERIK
Generic Entry Date for TAZVERIK*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for TAZVERIK
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Susan Chi | Phase 1/Phase 2 |
| Dr. Victor H.F. Lee | Phase 2 |
| Bristol-Myers Squibb | Phase 1/Phase 2 |
Anatomical Therapeutic Chemical (ATC) Classes for TAZVERIK
US Patents and Regulatory Information for TAZVERIK
TAZVERIK is protected by thirty-six US patents and five FDA Regulatory Exclusivities.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of TAZVERIK is See Plans and Pricing.
This potential generic entry date is based on patent See Plans and Pricing.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting TAZVERIK
Aryl- or heteroaryl-substituted benzene compounds
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF TREATING EPITHELIOID SARCOMA
Salt form of a human histone methyltransferase EZH2 inhibitor
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA BY INHIBITING EZH2
Salt form of a human histone methyltransferase EZH2 inhibitor
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA POSITIVE FOR AN ENHANCER OF ZESTE HOMOLOG 2 (EZH2) MUTATION BY INHIBITING EZH2
Salt form of a human histone methyltransferase EZH2 inhibitor
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF TREATING EPITHELIOID SARCOMA BY INHIBITING ENHANCER OF ZESTE HOMOLOG 2 (EZH2)
Method for treating cancer
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA POSITIVE FOR AN ENHANCER OF ZESTE HOMOLOG 2 (EZH2) MUTATION
Method for treating cancer
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA
Method for treating cancer
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF TREATING EPITHELIOID SARCOMA
Aryl-or heteroaryl-substituted benzene compounds
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA
Aryl-or heteroaryl-substituted benzene compounds
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA POSITIVE FOR AN ENHANCER OF ZESTE HOMOLOG 2 (EZH2) MUTATION
Aryl-or heteroaryl-substituted benzene compounds
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF TREATING EPITHELIOID SARCOMA
Method for treating cancer
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Salt form of a human histone methyltransferase EZH2 inhibitor
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Aryl-or heteroaryl-substituted benzene compounds
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF TREATING EPITHELIOID SARCOMA
Aryl-or heteroaryl-substituted benzene compounds
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF TREATING FOLLICULAR LYMPHOMA
Aryl- or heteroaryl-substituted benzene compounds
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Inhibitors of human EZH2 and methods of use thereof
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA POSITIVE FOR AN ENHANCER OF ZESTE HOMOLOG 2 (EZH2) MUTATION
Aryl- or heteroaryl-substituted benzene compounds
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA
Aryl- or heteroaryl-substituted benzene compounds
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA POSITIVE FOR AN ENHANCER OF ZESTE HOMOLOG 2 (EZH2) MUTATION
Inhibitors of human EZH2 and methods of use thereof
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA POSITIVE FOR AN ENHANCER OF ZESTE HOMOLOG 2 (EZH2) MUTATION
Aryl- or heteroaryl-substituted benzene compounds
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Inhibitors of human EZH2, and methods of use thereof
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA POSITIVE FOR AN ENHANCER OF ZESTE HOMOLOG 2 (EZH2) MUTATION
Inhibitors of human EZH2, and methods of use thereof
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA POSITIVE FOR AN ENHANCER OF ZESTE HOMOLOG 2 (EZH2) MUTATION
Inhibitors of human EZH2, and methods of use thereof
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA POSITIVE FOR AN ENHANCER OF ZESTE HOMOLOG 2 (EZH2) MUTATION
Salt form of a human histone methyltransferase EZH2 inhibitor
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA
Salt form of a human histone methyltransferase EZH2 inhibitor
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA POSITIVE FOR AN ENHANCER OF ZESTE HOMOLOG 2 (EZH2) MUTATION
Aryl- or heteroaryl-substituted benzene compounds
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF TREATING A LUNG METASTASIS OF EPITHELIOID SARCOMA
Aryl- or heteroaryl-substituted benzene compounds
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA POSITIVE FOR AN ENHANCER OF ZESTE HOMOLOG 2 (EZH2) MUTATION
Aryl- or heteroaryl-substituted benzene compounds
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA
Aryl- or heteroaryl-substituted benzene compounds
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF TREATING EPITHELIOID SARCOMA
Methods of treating cancer
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF TREATING EPITHELIOID SARCOMA
Aryl-or heteroaryl-substituted benzene compounds
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF TREATING EPITHELIOID SARCOMA
Salt form of a human histone methyltransferase EZH2 inhibitor
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF TREATING A LUNG METASTASIS OF EPITHELIOID SARCOMA
Method for treating cancer
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA
Method for treating cancer
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA POSITIVE FOR AN ENHANCER OF ZESTE HOMOLOG 2 (EZH2) MUTATION
Method for treating cancer
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF TREATING EPITHELIOID SARCOMA
Inhibitors of human EZH2, and methods of use thereof
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA POSITIVE FOR AN ENHANCER OF ZESTE HOMOLOG 2 (EZH2) MUTATION BY INHIBITING EZH2
FDA Regulatory Exclusivity protecting TAZVERIK
NEW CHEMICAL ENTITY
Exclusivity Expiration: See Plans and Pricing
TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL) WHOSE TUMORS ARE POSITIVE FOR AN EZH2 MUTATION AS DETECTED BY AN FDA-APPROVED TEST AND WHO HAVE RECEIVED AT LEAST 2 PRIOR SYSTEMIC THERAPIES
Exclusivity Expiration: See Plans and Pricing
TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL) WHO HAVE NO SATISFACTORY ALTERNATIVE TREATMENT OPTIONS
Exclusivity Expiration: See Plans and Pricing
INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA WHOSE TUMORS ARE POSITIVE FOR AN EZH2 MUTATION AS DETECTED BY AN FDA-APPROVED TEST AND WHO HAVE RECEIVED AT LEAST 2 PRIOR SYSTEMIC THERAPIES, AND FOR THE TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA WHO HAVE NO SATISFACTORY ALTERNATIVE TREATMENT OPTIONS
Exclusivity Expiration: See Plans and Pricing
INDICATED FOR THE TREATMENT OF ADULTS AND PEDIATRIC PATIENTS AGED 16 YEARS AND OLDER WITH METASTATIC OR LOCALLY ADVANCED EPITHELIOID SARCOMA NOT ELIGIBLE FOR COMPLETE RESECTION
Exclusivity Expiration: See Plans and Pricing
International Patents for TAZVERIK
When does loss-of-exclusivity occur for TAZVERIK?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Australia
Patent: 15350108
Estimated Expiration: See Plans and Pricing
Patent: 21204706
Estimated Expiration: See Plans and Pricing
Brazil
Patent: 2017010166
Estimated Expiration: See Plans and Pricing
Canada
Patent: 67664
Estimated Expiration: See Plans and Pricing
China
Patent: 7249591
Estimated Expiration: See Plans and Pricing
Eurasian Patent Organization
Patent: 1791095
Estimated Expiration: See Plans and Pricing
European Patent Office
Patent: 20916
Estimated Expiration: See Plans and Pricing
Israel
Patent: 2182
Estimated Expiration: See Plans and Pricing
Japan
Patent: 29684
Estimated Expiration: See Plans and Pricing
Patent: 17537899
Estimated Expiration: See Plans and Pricing
Patent: 21073241
Estimated Expiration: See Plans and Pricing
Mexico
Patent: 17006089
Estimated Expiration: See Plans and Pricing
Singapore
Patent: 201703806X
Estimated Expiration: See Plans and Pricing
South Korea
Patent: 2338802
Estimated Expiration: See Plans and Pricing
Patent: 170103768
Estimated Expiration: See Plans and Pricing
Patent: 210156840
Estimated Expiration: See Plans and Pricing
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering TAZVERIK around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| New Zealand | 706738 | Substituted benzene compounds | See Plans and Pricing |
| Russian Federation | 2662436 | СОДЕРЖАЩИЕ ЗАМЕСТИТЕЛИ БЕНЗОЛЬНЫЕ СОЕДИНЕНИЯ (SUBSTITUTED BENZENE COMPOUNDS) | See Plans and Pricing |
| Russian Federation | 2015118145 | ЗАМЕЩЕННЫЕ БЕНЗОЛЬНЫЕ СОЕДИНЕНИЯ | See Plans and Pricing |
| South Korea | 20190121386 | 아릴- 또는 헤테로아릴-치환된 벤젠 화합물 (- - ARYL- OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS) | See Plans and Pricing |
| Japan | 5933686 | See Plans and Pricing | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2022 - 2023
NCE-1 Patent Challenge Dates 2022 - 2023
ClinicalTrialExchange - Connecting volunteers and trials
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2022, www.DrugPatentWatch.com.
Follow DrugPatentWatch:
